{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:50:41Z","timestamp":1780350641372,"version":"3.54.1"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    During in-use stability testing of cefixime granules for oral suspension, an impurity with a relative retention time of 0.19 was consistently detected and increased during storage. To ensure regulatory compliance and patient safety, the impurity was structurally identified and toxicologically qualified. A laboratory-scale formulation and commercial products were studied under refrigerated and ambient conditions. The impurity was isolated by automated fraction collection and characterised by liquid chromatography-mass spectrometry and tandem mass spectrometry. Kinetic evaluation showed pseudo-first-order formation, with faster accumulation at ambient temperature. The impurity was identified as a\n                    <jats:italic>\u03b3<\/jats:italic>\n                    -lactone degradation product of cefixime, present as multiple stereoisomers stabilised under acidic conditions.\n                    <jats:italic>In silico<\/jats:italic>\n                    toxicological assessment using complementary platforms indicated no additional structural alerts, no mutagenic potential, and negligible acute toxicity. The impurity forms only after prolonged storage of reconstituted suspensions and is classified as an ICH M7 Class 5 impurity, requiring no further genotoxicity testing. The applied analytical-computational workflow provides an efficient approach for impurity qualification in\n                    <jats:italic>\u03b2<\/jats:italic>\n                    -lactam antibiotics.\n                  <\/jats:p>","DOI":"10.2478\/acph-2026-0005","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:59:36Z","timestamp":1774533576000},"page":"1-25","source":"Crossref","is-referenced-by-count":1,"title":["Predictive analytical workflow for rapid structure elucidation and\n                    <i>in silico<\/i>\n                    toxicological qualification of an unidentified impurity in cefixime granules for oral suspension"],"prefix":"10.2478","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9638-8486","authenticated-orcid":false,"given":"Ivana","family":"Mitrevska","sequence":"first","affiliation":[{"name":"Faculty of Medical Sciences Goce Delcev University , Stip Republic of North Macedonia"},{"name":"Quality Assurance, ALKALOID AD , Skopje , Republic of North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6817-7556","authenticated-orcid":false,"given":"Marina","family":"Chachorovska","sequence":"additional","affiliation":[{"name":"Research & Development ALKALOID AD , Skopje Republic of North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-0457","authenticated-orcid":false,"given":"Gjorgji","family":"Petrushevski","sequence":"additional","affiliation":[{"name":"Quality Control Pharmaceuticals ALKALOID AD , Skopje Republic of North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2026051108174645686_j_acph-2026-0005_ref_001","doi-asserted-by":"crossref","unstructured":"R. N. Brogden and D. M. Richards, Cefixime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential, Drugs 38(4) (1989) 524\u2013550; https:\/\/doi.org\/10.2165\/00003495-198938040-00004","DOI":"10.2165\/00003495-198938040-00004"},{"key":"2026051108174645686_j_acph-2026-0005_ref_002","unstructured":"S. C. Sweetman (Ed.), Martindale: The Complete Drug Reference, 33rd ed., Pharmaceutical Press, London 2002."},{"key":"2026051108174645686_j_acph-2026-0005_ref_003","unstructured":"T. I. Lucas, R. H. Bishara and R. H. Seevers, A stability program for the distribution of drug products, Pharm. Technol. 28(7) (2004) 68\u201373."},{"key":"2026051108174645686_j_acph-2026-0005_ref_004","unstructured":"European Medicines Agency, Note for guidance on in-use stability testing of human medicinal products, CPMP\/QWP\/2934\/99, EMA, London 2001."},{"key":"2026051108174645686_j_acph-2026-0005_ref_005","doi-asserted-by":"crossref","unstructured":"S. Kitamura, A. Miyamae, S. Koda and Y. Morimoto, Effect of grinding on the solid-state stability of cefixime trihydrate, Int. J. Pharm. 56(2) (1989) 125\u2013134; https:\/\/doi.org\/10.1016\/0378-5173(89)90005-7","DOI":"10.1016\/0378-5173(89)90005-7"},{"key":"2026051108174645686_j_acph-2026-0005_ref_006","doi-asserted-by":"crossref","unstructured":"S. Kitamura, S. Koda, A. Miyamae, T. Yasuda and Y. Morimoto, Dehydration effect on the stability of cefixime trihydrate, Int. J. Pharm. 59(3) (1990) 217\u2013224; https:\/\/doi.org\/10.1016\/0378-5173(90)90112-H","DOI":"10.1016\/0378-5173(90)90112-H"},{"key":"2026051108174645686_j_acph-2026-0005_ref_007","unstructured":"International Conference on Harmonisation, Impurities in new drug products Q3B(R2), ICH Harmo nised Tripartite Guideline, Step 4, Geneva 2006."},{"key":"2026051108174645686_j_acph-2026-0005_ref_008","unstructured":"European Medicines Agency, Guideline on setting specifications for related impurities in antibiotics, EMA\/CHMP\/CVMP\/QWP\/199250\/2009 corr., EMA, London 2012."},{"key":"2026051108174645686_j_acph-2026-0005_ref_009","unstructured":"R. Benigni, C. Bossa, N. Jeliazkova, T. Netzeva and A. Worth, The Benigni\/Bossa rulebase for mutagenicity and carcinogenicity, EUR 24895 EN, Publications Office of the European Union, Luxembourg 2011."},{"key":"2026051108174645686_j_acph-2026-0005_ref_010","doi-asserted-by":"crossref","unstructured":"R. Benigni, C. Bossa and O. Tcheremenskaia, In vitro cell transformation assays for an integrated assessment of carcinogenicity, Mutagenesis 28(1) (2013) 107\u2013116; https:\/\/doi.org\/10.1093\/mutage\/ges050","DOI":"10.1093\/mutage\/ges059"},{"key":"2026051108174645686_j_acph-2026-0005_ref_011","unstructured":"R. Benigni, C. Bossa, O. Tcheremenskaia and A. Worth, Development of structural alerts for the in vivo micronucleus assay in rodents, EUR 23981 EN, Publications Office of the European Union, Luxembourg 2009."},{"key":"2026051108174645686_j_acph-2026-0005_ref_012","doi-asserted-by":"crossref","unstructured":"R. Benigni and C. Bossa, Mechanisms of chemical carcinogenicity and mutagenicity: Implications for predictive toxicology, Chem. Rev. 111(4) (2011) 2507\u20132536; https:\/\/doi.org\/10.1021\/cr100222q","DOI":"10.1021\/cr100222q"},{"key":"2026051108174645686_j_acph-2026-0005_ref_013","unstructured":"United States Environmental Protection Agency, Toxicity Estimation Software Tool (TEST), EPA, Washington (DC) 2015."},{"key":"2026051108174645686_j_acph-2026-0005_ref_014","unstructured":"United States Environmental Protection Agency, User\u2019s Guide for T.E.S.T., EPA, Washington (DC) 2012."},{"key":"2026051108174645686_j_acph-2026-0005_ref_015","doi-asserted-by":"crossref","unstructured":"T. M. Martin, P. Harten, R. Venkatapathy, S. Das and D. M. Young, A hierarchical clustering metho dology for toxicity estimation, Toxicol. Mech. Methods 18(2\u20133) (2008) 251\u2013266; https:\/\/doi.org\/10.1080\/15376510701857395","DOI":"10.1080\/15376510701857353"},{"key":"2026051108174645686_j_acph-2026-0005_ref_016","unstructured":"QSAR Toolbox, Version 3.3, OECD, Paris; http:\/\/www.qsartoolbox.org"},{"key":"2026051108174645686_j_acph-2026-0005_ref_017","doi-asserted-by":"crossref","unstructured":"A. Sutter, A. Amberg, S. Boyer, A. Brigo, J. F., Contrera, L. L. Custer, K. L. Dobo, V. Gervais, S. Glowienke, J. van Gompel, N. Greene, W. Muster, J. Nicolette, M. Vijayaraj Reddy, V. Thybaud, E. Vock, A. T. White and L. M\u00fcller, Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities, Regul. Toxicol. Pharmacol. 67(1) (2013) 39\u201352; https:\/\/doi.org\/10.1016\/j.yrtph.2013.05.001","DOI":"10.1016\/j.yrtph.2013.05.001"},{"key":"2026051108174645686_j_acph-2026-0005_ref_018","doi-asserted-by":"crossref","unstructured":"J. F. Contrera, Validation of Toxtree and SciQSAR predictive software, Regul. Toxicol. Pharmacol. 67(2) (2013) 285\u2013293; https:\/\/doi.org\/10.1016\/j.yrtph.2013.08.012","DOI":"10.1016\/j.yrtph.2013.08.008"},{"key":"2026051108174645686_j_acph-2026-0005_ref_019","doi-asserted-by":"crossref","unstructured":"S. M. Pawar and S. R. Dhaneshwar, Stability-indicating HPTLC method for desvenlafaxine, J. Liq. Chromatogr. Relat. Technol. 35(4) (2012) 449\u2013510; https:\/\/doi.org\/10.1080\/10826076.2011.601500","DOI":"10.1080\/10826076.2011.601500"},{"key":"2026051108174645686_j_acph-2026-0005_ref_020","doi-asserted-by":"crossref","unstructured":"D. Saini, S. Baboota, M. Ali, H. Patel, P. Jain, S. Neerumulla and J. Ali, Stability-indicating UPLC method for raloxifene hydrochloride, J. Liq. Chromatogr. Relat. Technol. 35(2) (2012) 162\u2013173; https:\/\/doi.org\/10.1080\/10826076.2011.597067","DOI":"10.1080\/10826076.2011.597067"},{"key":"2026051108174645686_j_acph-2026-0005_ref_021","doi-asserted-by":"crossref","unstructured":"K. M. Al Azzam, B. Saad, A. Makahleah, H. Y. Aboul-Enein and A. A. Elbashir, MEKC assay for valacyclovir and impurities, Biomed. Chromatogr. 24(5) (2010) 535\u2013543; https:\/\/doi.org\/10.1002\/bmc.1323","DOI":"10.1002\/bmc.1323"},{"key":"2026051108174645686_j_acph-2026-0005_ref_022","doi-asserted-by":"crossref","unstructured":"R. Sehrawat, M. Maithani and R. Singh, Regulatory aspects of stability-indicating methods, Chroma tographia 72(1\u20132) (2010) 1\u20136; https:\/\/doi.org\/10.1365\/s10337-010-1612-z","DOI":"10.1365\/s10337-010-1612-z"},{"key":"2026051108174645686_j_acph-2026-0005_ref_023","doi-asserted-by":"crossref","unstructured":"Z. Talebpour, H. Pourabdollahi, H. Rafati, A. Abdollahpour, Y. Bashour and H. Y. Aboul-Enein, Determination of cefixime by a validated stability-indicating HPLC method and identification of its related substances by LC-MS\/MS studies, Sci. Pharm. 81(2) (2013) 493\u2013503; https:\/\/doi.org\/10.3797\/scipharm.1301-15","DOI":"10.3797\/scipharm.1301-15"},{"key":"2026051108174645686_j_acph-2026-0005_ref_024","unstructured":"E. H. K. Adam, A. E. M. Saeed and I. E. Barakat, Degradation of cefixime trihydrate under stress conditions, Der Pharma Chem. 3(6) (2011) 197\u2013207."},{"key":"2026051108174645686_j_acph-2026-0005_ref_025","doi-asserted-by":"crossref","unstructured":"Y. Namiki, T. Tanabe, T. Kobayashi, J. Tanabe, Y. Okimura, S. Koda and Y. Morimoto, Degradation kinetics and mechanisms of a new cephalosporin, cefixime, in aqueous solution, J. Pharm. Sci. 76(3) (1987) 208\u2013214; https:\/\/doi.org\/10.1002\/jps.2600760305","DOI":"10.1002\/jps.2600760305"},{"key":"2026051108174645686_j_acph-2026-0005_ref_026","doi-asserted-by":"crossref","unstructured":"H. Wang, H. Huang, J. Cao, D. Chui and S. Xiao, Mass spectral differentiation of b-lactams, Biomed. Res. Int. 2015 (2015) Article ID 697958 (13 pages); https:\/\/doi.org\/10.1155\/2015\/697958","DOI":"10.1155\/2015\/697958"},{"key":"2026051108174645686_j_acph-2026-0005_ref_027","unstructured":"A. D. Deshpande, K. G. Baheti and N. R. Chatterjee, Degradation of b-lactam antibiotics, Curr. Sci. 87(12) (2004) 1684\u20131695."},{"key":"2026051108174645686_j_acph-2026-0005_ref_028","doi-asserted-by":"crossref","unstructured":"D. Wang and R. E. Notari, Cefuroxime hydrolysis kinetics in aqueous solution, J. Pharm. Sci. 83(4) (1994) 577\u2013581; https:\/\/doi.org\/10.1002\/jps.2600830420","DOI":"10.1002\/jps.2600830427"},{"key":"2026051108174645686_j_acph-2026-0005_ref_029","doi-asserted-by":"crossref","unstructured":"A. Uzunovi\u0107, E. Vrani\u0107 and J. Had\u017eiabdi\u0107, Stability of cefuroxime axetil oral suspension, Bosn. J. Basic Med. Sci. 8(1) (2008) 93\u201396; https:\/\/doi.org\/10.17305\/bjbms.2008.3005","DOI":"10.17305\/bjbms.2008.3005"}],"container-title":["Acta Pharmaceutica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/acph-2026-0005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:23:21Z","timestamp":1778487801000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/acph-2026-0005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,25]]},"published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.2478\/acph-2026-0005"],"URL":"https:\/\/doi.org\/10.2478\/acph-2026-0005","relation":{},"ISSN":["1846-9558"],"issn-type":[{"value":"1846-9558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}